For chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema.
Give by IV infusion at a rate of 0.08mL/kg/min. 60mg/kg once weekly. Monitor infusion rates and clinical state closely during infusion.
History of anaphylaxis or severe systemic response to A1-PI products. Selective IgA deficiencies who have known antibodies against IgA.
Contains human plasma; monitor for possible infection transmission. Risk of circulatory overload. Pregnancy (Cat.C). Nursing mothers.
Asthenia, inj site pain, dizziness, headache, paresthesia, pruritus; hypersensitivity reactions (discontinue if occur).
Single-use vial—1 (w. diluent + vented transfer device)